Optimal management of cytomegalovirus retinitis in patients with AIDS

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 285-299

  Stewart, Michael W ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Aids; Cytomegalovirus; Immune recovery uveitis; Retinal detachment; Retinitis; Treatment

Indexed keywords

ABACAVIR; CIDOFOVIR; CORTICOSTEROID; ENFUVIRTIDE; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROBENECID; PROTEINASE INHIBITOR; RALTEGRAVIR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VALGANCICLOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; AREA UNDER THE CURVE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; DEVELOPING COUNTRY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG OVERDOSE; DRUG WITHDRAWAL; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE STATUS; IMPLANTATION; INCIDENCE; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; IRITIS; KIDNEY FAILURE; LEUKOPENIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PATIENT SELECTION; PERSONNEL SHORTAGE; REPRODUCTIVE TOXICITY; RETINA DETACHMENT; RETINA MACULA LUTEA; REVIEW; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; SUSTAINED DRUG RELEASE; THROMBOCYTOPENIA; UVEITIS; VISUAL IMPAIRMENT; VITRECTOMY; VOMITING;

EID: 77953406689     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s6700     Document Type: Review

References (111)

1. Kedhar SR, Jabs DA. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes. 2007;14:66-71.
2. Staras SAS, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43:1143-1151.
3. Drew WL, Mitz L, Miner RC, et al. Prevalence of cytomegalovirus infection in homosexual males. J Infect Dis. 1981;143:188-192.
4. Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166:1223-1227.
5. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305:1425-1431.
6. Masur H, Michelis MA, Greene JB, et al. An outbreak of communityacquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305:1431-1438.
7. Holland GN, Gottlieb MS, Yee RD, et al. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol. 1982;93:393-402.
8. Holland GN, Buhles WC, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy Study Group. Arch Ophthalmol. 1989;107:1759-1766.
9. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Am J Ophthalmol. 1997;124:141-157.
10. Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988;109:963-969.
11. + counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:575-582.
12. Pertel P, Hirschtick RE, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5:1069-1074.
13. Definition of HAART. Available from: http://statepiaps.jhsph.edu/wihs/Invest-info/Def-haart.pdf. Accessed on January 10, 2010.
14. Skiest DJ. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). Am J Med Sci. 1999;317:318-335.
15. Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS. 1. Ocular diagnoses at enrollment. Ophthalmology. 2007;114:780-786.
16. Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS. 2. Ocular examination results at enrollment. Ophthalmology. 2007;114:787-793.
17. Holland GN, Vaudaux JD, Shiramizu KM, et al. Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000). Am J Ophthalmol. 2008;145:12-22.
18. Jabs DA, van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133:48-61.
19. Jabs DA, van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004;111: 2232-2239.
20. Jabs DA, van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004;111:2224-2231.
21. Jabs DA, Holbrook JT, van Natta ML, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2005;112:771-779.
22. Lalezari JP, Friedberg DN, Bisset J, et al. High dose oral ganciclovir treatment for cytomegalovirus retinitis. J Clin Virol. 2002;24: 67-77.
23. Noble S, Faulds D. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 1998;56:115-146.
24. Faulds D, Heel RC. Ganciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39:597-638.
25. Markham A, Faulds D. Ganciclovir: An update of its therapeutic use in cytomegalovirus infection. Drugs. 1994;48:455-484.
26. Boivin G, Gilbert C, Gaudreau A, et al. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis. 2001;184:1598-1602.
27. Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;135:26-34.
28. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71:154-163.
29. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients [Consensus article IHMF management recommendations]. Herpes. 2004;11:77-86.
30. De Clerq E. Antiviral drugs in current clinical use. J Clin Virol. 2004;30:115-133.
31. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 1995;333:615-620.
32. Martin DF, Kupperman BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med. 1999;340:1063-1070.
33. Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167-176.
34. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV-and CMV-seropositive subjects. J Clin Pharmacol. 1999;39: 800-804.
35. Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987;103:17-23.
36. Young SH, Morlet N, Henry S, et al. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust. 1992;157: 370-373.
37. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991;98: 1348-1353.
38. Diaz-Llopis M, Chipont E, Sanchez, et al. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;114:742-747.
39. Lieberman RM, Orellana J, Melton RC. Efficacy of intravitreous foscarnet in a patient with AIDS. N Engl J Med. 2004;330:868-869.
40. Diaz-Llopis M, Espana E, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol. 1994;78:120-124.
41. Package insert. Vistide (cidofovir, Foster City, CA: Gilead Sciences, September 1996).
42. Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology. 1996;103:1078-1083.
43. Kupperman B, Wolitz R, Stagg R, et al. A Phase II randomized, double-masked study of intraocular cidofovir for relapsing cytomegalovirus retinitis in patients with AIDS [Abstract]. Presented at the Vitreous Society Annual Meeting. Cancun, Mexico, December 8-12, 1996.
44. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
45. Kempen JH, Jabs DA, Wilson LA, et al. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Am J Ophthalmol. 2005;139:1028-1034.
46. Kempen JH, Jabs DA, Wilson LA, et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis. 2003;37:1365-1373.
47. Jabs DA, Holbrook JT, van Natta ML, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2005;112:771-779.
48. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med. 1997;337:83-90.
49. Cvetkovic RS, Wellington K. Valganciclovir: A review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65:859-878.
50. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The Cytomegalovirus retreatment trial. Arch Ophthalmol. 1996;114:23-33.
51. Jacobson MA. Drug therapy: treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:105-114.
52. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The ganciclovir cidofovir cytomegalovirus retinitis trial. Am J Ophthalmol. 2001;131:457-467.
53. Kupperman BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993;168:1506-1509.
54. Aravelo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis. 1995;172:951-956.
55. Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis. 1998;177:770-773.
56. Jabs DA, Enger C, Dunn JP, Forman M. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42:2240-2244.
57. Weinberg A, Jabs DA, Chou S, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2003;187: 777-784.
58. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-1126.
59. Plosker GL, Noble S. Cidofovir: A review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs. 1999;58:325-345.
60. Walmsley S, Tseng A. Comparative tolerability of therapies for cytomegalovirus therapy. Drug Saf. 1999;21:203-224.
61. Acharya N, Young L. Sustained-release drug implants for the treatment of intraocular disease. Int Ophthalmol Clin. 2004;44:33-39.
62. Jabs DA. AIDS and Ophthalmology, 2008. Arch Ophthalmol. 2008;126:1143-1146.
63. Mahadevia PJ, Gebo KA, Pettit K, et al. The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-HAART era among a national managed-care population. J Acquir Immune Defic Syndr. 2004;36:972-977.
64. Walmsley SL, Raboud J, Angel JB, et al. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. HIV Clin Trials. 2006;7:1-9.
65. Martin BK, Ricks MO, Forman MS, Jabs DA. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis. 2007;44:1001-1008.
66. Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53:1-112.
67. Holland GN. Discussion of MacDonald JC, Karavellas MP, Torriani FJ, et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology. 2000;107:877-833.
68. Wohl DA, Kendall MA, Owens S, et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials. 2005;6:136-146.
69. Jabs DA, Martin BK, Forman MS, Ricks MO. Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitis. J Infect Dis. 2005;192:640-649.
70. Holland GN. AIDS and Ophthalmology: The first quarter century. Am J Ophthalmol. 2008;145:397-408.
71. Skiest DJ. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). Am J Med Sci. 1999;317:318-335.
72. Kempen JH, Frick KD, Jabs DA. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS. Pharmacoeconnomics. 2001;19:1199-1208.
73. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): Review of common infectious manifestations and treatment options. AIDS Research and Therapy. 2007;4:9.
74. Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology. 2006;113:684-694.
75. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV infected patients. Clin Infect Dis. 2004;38:1159-1166.
76. Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006;113:1423-1440.
77. French MA. The immunopathogenesis of mycobacterial immune restoration disease. Lancet Infect Dis. 2006;6:461-462.
78. Karavellas MP, Plummer DJ, MacDonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infectious Dis. 1999;179:697-700.
79. Kempen JH, Min YI, Freeman WR, et al. Risk of immunity recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology. 2006;113:684-694.
80. Schrier RD, Song MK, Smith IL, et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina. 2006;26:165-169.
81. Westeneg AC, Rothova A, De Boer JH, Groot-Mijnes JD. Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. Am J Ophthalmol. 2007;144:781-785.
82. Ortega-Larrocea G, Espinosa E, Reyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy. AIDS. 2005;19:735-738.
83. Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol. 1999;83:540-545.
84. Karavellas MP, Azen SP, Macdonald C, et al. Immune recovery uveitis and uveitis in AIDS: Clinical predictors, sequellae and treatment outcome. Retina. 2001;21:1-9.
85. El-Bradey M, Cheng L, Song M, et al. Long term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach. Retina. 2004;24:376-382.
86. Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol. 1999;83:540-545.
87. Rothova A. Inflammatory cystoid macular oedema. Current Opinion Ophthalmol. 2007;18:487-492.
88. Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide implant. Am J Ophthalmol. 2007;143:334-335.
89. Morrison VL, Kozak I, LaBree LD, et al. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology. 2007;114:334-339.
90. Canzano JC, Morse LS, Wendel RT. Surgical repair of cytomegalovirusrelated retinal detachment without silicone oil in patients with AIDS. Retina. 1999;19:274-280.
91. Davis J. Removing silicone oil from eyes with cytomegalovirus retinitis. Am J Ophthalmol. 2005;140:900-902.
92. Kestelyn P. The epidemiology of CMV retinitis in Africa. Ocul Immunol Inflamm. 1999;7:173-177.
93. Shah SU, Kerkar SP, Pazare AR. Evaluation of ocular manifestations and blindness in HIV/AIDS patients on HAART in a tertiary care hospital in western India. Br J Ophthalmol. 2009;93:88-90.
94. Gharai S, Venkatesh P, Garg S, et al. Ophthalmic manifestations of HIV infections in India in the era of HAART: Analysis of 100 consecutive patients evaluated at a tertiary eye care center in India. Ophthalmic Epidemiol. 2008;15(4):264-271.
95. Biswas J, Madhavan HN, George AE, et al. Ocular lesions associated with HIV infection in India: A series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol. 2000;129:9-15.
96. Biswas PN, Saha B, Ghosh S, et al. Ophthalmic manifestations in people living with HIV attending a tertiary care centre of Eastern India. J Indian Med Assoc. 2008;106:292-294.
97. Nkomazana O, Tshitswana D. Ocular complications of HIV infection in sub-Sahara Africa. Curr HIV/AIDS Rep. 2008;5:120-125.
98. Nwosu NN. HIV/AIDS in ophthalmic patients: The Guinness Eye Centre Onitsha experience. Niger Postgrad Med J. 2008;15:24-27.
99. T/Giorgis A, Melka, G/Mariam A. Ophthalmic manifestation of aids in Armed Forces General Teaching Hospital, Addis Ababa. Ethiop Med J. 2007;45:327-334.
100. Osahon Al, Onunu AN. Ocular disorders in patients infected with the human immunodeficiency virus at the University of Benin Teaching Hospital, Benin City, Nigeria. Niger J Clin Pract. 2007;10(4):283-286.
101. Manosuthi W, Chaovavanich A, Tansuphaswakiful S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect. 2007;55:464-469.
102. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med. 1996;335:377-383.
103. Nichols CW. Mycobacterium avium complex infection, rifabutin, and uveitis - is there a connection? Clin Infect Dis. 1996;22:S43-S47.
104. Cochereau I, Mlika-Cabanne N, Godinaud P, et al. AIDS related eye disease in Burundi, Africa. Br J Ophthalmol. 1999;83:339-342.
105. Weng TN, Versace P. Ocular association of HIV infection in the era of highly active antiretroviral therapy and the global perspective. Clin Exp Ophthalmol. 2005;33:317-329.
106. Ausayakhun S, Watananiforn S, Ngamtiphakorn S, Prasitsilp J. Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS. J Med Assoc Thai. 2005;88:103-107.
107. Teerawattananon K, Iewsakul S, Yenjitr C, et al. Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study. Pharmacoeconomics. 2007;25:413-428.
108. Chiou SH, Liu CY, Hsu WM, et al. Ophthalmic findings in patients with acquired immunodeficiency syndrome. J Microbiol Immunol Infect. 2000;33:45-48.
109. DeCock KM, Lucas SB, Lucas S, et al. Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. Am J Public Health. 1993;83:1385-1389.
110. National AIDS Control Organization, Ministry of Health and Family Welfare, Government of India. Programme implementation guidelines for phased scale up of access to antiretroviral therapy for people living with HIV/AIDS. Mumbai, India: National AIDS Control Organization; 2004.
111. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1- infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367: 817-824.